GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocytogen Pharmaceuticals (Beijing) Co Ltd (HKSE:02315) » Definitions » EV-to-FCF

Biocytogen Pharmaceuticals (Beijing) Co (HKSE:02315) EV-to-FCF : -28.06 (As of May. 30, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Biocytogen Pharmaceuticals (Beijing) Co EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Biocytogen Pharmaceuticals (Beijing) Co's Enterprise Value is HK$6,239.1 Mil. Biocytogen Pharmaceuticals (Beijing) Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-222.3 Mil. Therefore, Biocytogen Pharmaceuticals (Beijing) Co's EV-to-FCF for today is -28.06.

The historical rank and industry rank for Biocytogen Pharmaceuticals (Beijing) Co's EV-to-FCF or its related term are showing as below:

HKSE:02315' s EV-to-FCF Range Over the Past 10 Years
Min: -30.21   Med: -14.23   Max: -6.23
Current: -30.21

During the past 4 years, the highest EV-to-FCF of Biocytogen Pharmaceuticals (Beijing) Co was -6.23. The lowest was -30.21. And the median was -14.23.

HKSE:02315's EV-to-FCF is ranked worse than
100% of 370 companies
in the Biotechnology industry
Industry Median: 8.835 vs HKSE:02315: -30.21

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-30), Biocytogen Pharmaceuticals (Beijing) Co's stock price is HK$8.72. Biocytogen Pharmaceuticals (Beijing) Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-1.050. Therefore, Biocytogen Pharmaceuticals (Beijing) Co's PE Ratio for today is At Loss.


Biocytogen Pharmaceuticals (Beijing) Co EV-to-FCF Historical Data

The historical data trend for Biocytogen Pharmaceuticals (Beijing) Co's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocytogen Pharmaceuticals (Beijing) Co EV-to-FCF Chart

Biocytogen Pharmaceuticals (Beijing) Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EV-to-FCF
- - -16.53 -22.15

Biocytogen Pharmaceuticals (Beijing) Co Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-FCF Get a 7-Day Free Trial - - -16.53 - -22.15

Competitive Comparison of Biocytogen Pharmaceuticals (Beijing) Co's EV-to-FCF

For the Biotechnology subindustry, Biocytogen Pharmaceuticals (Beijing) Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biocytogen Pharmaceuticals (Beijing) Co's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biocytogen Pharmaceuticals (Beijing) Co's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Biocytogen Pharmaceuticals (Beijing) Co's EV-to-FCF falls into.



Biocytogen Pharmaceuticals (Beijing) Co EV-to-FCF Calculation

Biocytogen Pharmaceuticals (Beijing) Co's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=6239.104/-222.326
=-28.06

Biocytogen Pharmaceuticals (Beijing) Co's current Enterprise Value is HK$6,239.1 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Biocytogen Pharmaceuticals (Beijing) Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-222.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biocytogen Pharmaceuticals (Beijing) Co  (HKSE:02315) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Biocytogen Pharmaceuticals (Beijing) Co's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=8.72/-1.050
=At Loss

Biocytogen Pharmaceuticals (Beijing) Co's share price for today is HK$8.72.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Biocytogen Pharmaceuticals (Beijing) Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-1.050.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Biocytogen Pharmaceuticals (Beijing) Co EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Biocytogen Pharmaceuticals (Beijing) Co's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Biocytogen Pharmaceuticals (Beijing) Co (HKSE:02315) Business Description

Traded in Other Exchanges
Address
12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, CHN
Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma and other advanced solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC) and other solid tumors.
Executives
Bvcf Realization Fund, L.p. 2201 Interest of corporation controlled by you
Zhao Yin Guo Ji Jin Rong You Xian Gong Si 2201 Interest of corporation controlled by you
Zhao Yin Guo Ji Jin Rong Kong Gu You Xian Gong Si 2201 Interest of corporation controlled by you
Prowell Ventures Pte Ltd 2201 Interest of corporation controlled by you
Gic Special Investments Private Limited 2102 Investment manager
Gic Private Limited 2201 Interest of corporation controlled by you
Gic (ventures) Pte. Ltd. 2201 Interest of corporation controlled by you
Yang Zhi 2201 Interest of corporation controlled by you
Innoveda Medtech, Ltd. 2201 Interest of corporation controlled by you
Ni Jian
Bvcf Realization Fund Gp, Ltd. 2201 Interest of corporation controlled by you
Bioveda China Fund Ii Rmb, Limited 2101 Beneficial owner
Cmbi Private Equity Series Spc 2201 Interest of corporation controlled by you
Cmb International Private Investment Limited 2201 Interest of corporation controlled by you
Cmb International Investment Management Limited 2201 Interest of corporation controlled by you

Biocytogen Pharmaceuticals (Beijing) Co (HKSE:02315) Headlines

No Headlines